Molecular and immunological aspects of p53 and p53-autoantibodies in head and neck squamous cell carcinoma

Oncology Reports

Volumn 22, Issue 6, 2009, Pages 1299-1303

  Cordes, Christian ^a   Von Lingen, J ^a   Gorogh T ^a   Ambrosch, P ^a   Gottschlich, S ^a   Hoffmann, M ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Autoantibodies; Cancer; p53; Squamous cell carcinoma

Indexed keywords

ARGININE; ASPARTIC ACID; AUTOANTIBODY; CYSTEINE; GLYCINE; HISTIDINE; LEUCINE; METHIONINE; PROTEIN P53; VALINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CARCINOMA, SQUAMOUS CELL; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70449361909     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000568     Document Type: Article

References (32)

1. Koh JY, Cho NP, Kong G, Lee JD and Yoon K: p53 mutations and human papillomavirus DNA in oral squamous cell carcinoma: Correlation with apoptosis. Br J Cancer 78: 354-359, 1998.
2. Field JK, Spandidos DA, Malliri A, Gosney JR, Yiagnisis M and Stell PM: Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br J Cancer 64: 573-577, 1991.
3. Field JK, Spandidos DA and Stell PM: Overexpression of p53 gene in head-and-neck cancer, linked with heavy smoking and drinking. Lancet 339: 502-503, 1992.
4. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991.
5. Woods DB and Vousden KH: Regulation of p53 function. Exp Cell Res 264: 56-66, 2001.
6. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V and Koeffler HP: Human p53 gene localized to short arm of chromosome 17. Nature 319: 783-784, 1986.
7. Strickler JG, Zheng J, Shu Q, Burgart LJ, Alberts SR and Shibata D: p53 mutations and microsatellite instability in sporadic gastric cancer. Cancer Res 54: 4750-4755, 1994.
8. Crawford LV, Pim DC and Bulbrooke AD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403-408, 1982.
9. El Sayed ZA, Farag DH and Eissa S: Tumor suppressor protein p53 and anti-p53 autoantibodies in pediatric rheumatological diseases. Pediatr Allergy Immunol 14: 229-233, 2003.
10. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J and Soussi T: Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 345: 621-622, 1995.
11. Gumus E, Erdamar S, Demirel G, Horasanli K, Kendirci M and Miroglu C: Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol 11: 1070-1077, 2004.
12. Gottschlich S, Hoffmann M, Maass JD, et al: p53 autoantibodies as tumor marker in head and neck squamous cell cancer. Anticancer Res 23: 913-915, 2003.
13. Lubin R, Schlichtholz B, Bengoufa D, et al: Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 53: 5872-5875, 1993.
14. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP: Development of antibodies against p53 in lung cancer patients appear to be dependent on the type of p53 mutation. Cancer Res 52: 4168-4174, 1992.
15. Schlichtholz B, Legros Y, Gillet D, et al: The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380-6384, 1992.
16. Maass JD, Gottschlich S, Goeroegh T, Lippert BM and Werner JA: Head and neck cancer and p53-immunogenicity. Anticancer Res 17: 2873-2874, 1997.
17. Sanger F, Nicklen S and Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74: 5463-5467, 1977.
18. Lane DP and Crawford LV: T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263, 1979.
19. Hammel P, Boissier B, Chaumette MT, et al: Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 40: 356-361, 1997.
20. Sidransky D, Tokino T, Hamilton SR, et al: Identification of ras oncogene mutations in the stool of patients with respectable colorectal cancer. Science 256: 102-105, 1992.
21. Gottschlich S, Folz BJ, Goeroegh T, Lippert BM, Maass JD and Werner JA: A new prognostic indicator for head and neck cancer-p53 serum antibodies? Anticancer Res 19: 2703-2705, 1999.
22. Wollenberg B, Jan NV, Pitzke P, Reiter W and Stieber P: Anti-p53 antibodies in serum of smokers and head and neck cancer patients. Anticancer Res 17: 413-418, 1997.
23. Ralhan R, Arora S, Chattopadhyay TK, Shukla NK and Mathur M: Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer 85: 791-795, 2000.
24. von Brevern MC, Hollstein MC, Cawley HM, et al: Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 56: 4917-4921, 1996.
25. Angelopoulou K, Yu H, Bharaj B, Giai M and Diamandis EP: p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clin Biochem 33: 53-62, 2000.
26. Collet B, Raoul JL, Le Berre N, et al: Serum anti-p53 antibodies in patients with squamous cell carcinoma of the esophagus: Comparison with p53 alterations and lymph node invasion. Int J Oncol 11: 617-621, 1997.
27. Labrecque S, Naor N, Thomson D and Matlashewski G: Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 53: 3468-3471, 1993.
28. Lubin R, Schlichtholz B, Teillaud JL, et al: p53 antibodies in patients with various types of cancer: assay, identification and characterization. Clin Cancer Res 1: 1463-1469, 1995.
29. Lavieille JP, Lubin R, Soussi T, Reyt E, Brambilla C and Riva C: Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. Anticancer Res 16: 2385-2388, 1996.
30. Davidoff AM, Iglehart JD and Marks JR: Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Nat Acad Sci USA 89: 3439-3442, 1992.
31. Warnakulasuriya S, Soussi T, Maher R, Johnson N and Tavassoli M: Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients. J Pathol 192: 52-57, 2000.
32. Dolcetti R, Doglioni C, Maestro R, et al: p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. Int J Cancer 52: 178-182, 1992.